This document discusses recent advances in the pharmacotherapy of asthma. It begins with a brief history of asthma and then covers the pathogenesis and management of the disease. New drug targets and classes that are being researched include ultra-long-acting bronchodilators, bitter taste receptor agonists, dissociated corticosteroids, lipid mediator antagonists targeting prostaglandins and leukotrienes, cytokines like IL-4, IL-5, and IL-13, phosphodiesterase inhibitors, adhesion molecule blockers, and monoclonal antibodies against IgE and mast cell stabilizers. The goal is to develop safer and more effective treatments that can modify the long-term course of asthma.
Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the Cysteinyl leukotriene CysLT1 receptor. Each 10 mg film-coated Loctril tablet contains 10.4 mg Montelukast sodium, which is equivalent to 10 mg of Montelukast.
Reference:
K. D. Tripathi. Essentials of Medical Pharmacology, 6th edition. Jaypee Publication Pg. No. 213-230.
This slide deck give detail presentation on causes, pathophysiology and pharmacotherapy of bronchial asthma.
For all IV video lecture series of this topic click:
https://youtube.com/playlist?list=PLBVbJ9HCa1BYdASIBMWSjjSL7zVHHVW1l
- For More Such Learning You Can Subscribe to My YouTube Channel.
https://www.youtube.com/channel/UC5o-WkzmDJaF7udyAP2jtgw/featured?sub_confirmation=1
Facebook Page: https://www.facebook.com/asacademylearningforever
Website Blog: https://itasacademy.blogspot.com/
Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the Cysteinyl leukotriene CysLT1 receptor. Each 10 mg film-coated Loctril tablet contains 10.4 mg Montelukast sodium, which is equivalent to 10 mg of Montelukast.
Reference:
K. D. Tripathi. Essentials of Medical Pharmacology, 6th edition. Jaypee Publication Pg. No. 213-230.
This slide deck give detail presentation on causes, pathophysiology and pharmacotherapy of bronchial asthma.
For all IV video lecture series of this topic click:
https://youtube.com/playlist?list=PLBVbJ9HCa1BYdASIBMWSjjSL7zVHHVW1l
- For More Such Learning You Can Subscribe to My YouTube Channel.
https://www.youtube.com/channel/UC5o-WkzmDJaF7udyAP2jtgw/featured?sub_confirmation=1
Facebook Page: https://www.facebook.com/asacademylearningforever
Website Blog: https://itasacademy.blogspot.com/
we are going to discuss asthma and COPD in the pharmacologicl perspective.
this presentation is done by :
Fatimah Fathi - Noura Bandar - Ahad Fahid - Shuruq Fahad
we are going to discuss asthma and COPD in the pharmacologicl perspective.
this presentation is done by :
Fatimah Fathi - Noura Bandar - Ahad Fahid - Shuruq Fahad
Educational and therapeutic topic on asthma for MBBS and MD pharmacology students. other students like BDS , BHMS, BAMS etc can use for knowledge. and academic purpose.
Made by Ranjith R Thampi. A decent powerpoint on Bronchial Asthma, a short summary on various presentations and treatment options starting at Primary health level. Was made mainly for Primary Health setup. I've also added options at higher centres and also a few references for latest drug modalities and use.
These lecture notes were prepared by Dr. Hamdi Turkey- Pulmonologist- Department of internal medicine - Taiz university
Do Not Forget To Visit Our Pages On Facebook on the following Links:
https://www.facebook.com/groups/569435236444761/
AND
https://www.facebook.com/groups/690331650977113/
Bronchial asthma for pharnacy student.pptxmekulecture
Under normal conditions, only approximately 1 mL of the 125 mL of glomerular filtrate that is formed each minute is excreted in the urine.
The other 124 mL is reabsorbed in the tubules.
This means that the average output of urine is approximately 60 mL/hour… approximately 1.5L urine per day.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Are There Any Natural Remedies To Treat Syphilis.pdf
Recent advances in the pharmacotherapy of asthma
1. Recent Advances in the Pharmacotherpy
of Asthma
Dr. Mohit Kulmi
Postgraduate resident
Department of Pharmacology
SAMC & PGI, Indore
2. History
• Asthma : derived from the Greek aazein, meaning "sharp breath.“
• In 450 BC. Hippocrates: more likely to occur in tailors, anglers,
and metalworkers.
• Six centuries later, Galen: caused by partial or complete bronchial
obstruction.
• 1190 AD, Moses Maimonides: wrote a treatise on asthma, describing
its prevention, diagnosis, and treatment
• 17th century, Bernardino Ramazzini: connection between asthma
and organic dust.
• 1901: The use of bronchodilators started.
• 1960s: inflammatory component of asthma was recognized and
anti-inflammatory medications were added to the regimens.
3. Simple Definition
It’s a reversible chronic inflammatory airway
disease which is characterized by bronchial
hyper-responsiveness of the airways to various
stimuli, leading to widespread
bronchoconstriction, airflow limitation and
inflammation of the bronchi causing symptoms of
cough, wheeze, chest tightness and dyspnoea.
4. • Bronchial asthma Patients with asthma experience:
• Attacks of severe dyspnea, coughing, and wheezing.
• Rarely, “status asthmaticus” - may prove fatal.
• Patients may be asymptomatic between the attacks.
• In some cases, the attacks are triggered by exercise and cold or by
exposure to an allergen, but often no trigger can be identified.
• There has been a significant increase in the incidence of asthma in
the world in the past three decades.
5.
6. • Genetic factors
• Environmental factors
• House dust
• Mites
• Exposure to tobacco smoke,
• to animals, pollens, molds.
• Dietary changes
• junk food and fast food contain MSG
ETIOLOGY OF ASTHMA
7. Lack of exercise
• Less stretching of the airways
Occupational exposure
• Irritants in the workplace : chemicals, dusts, gases, moulds and
pollens.
• These can be found in industries such as baking, spray painting of
cars, woodworking, chemical production, and farming.
8. • Atopic diseases – eczema and allergic rhinitis.
• Maternal status – both physical and mental conditions like
anaemia and depression in the mother are associated with asthmatic
stress for the child.
• Early antibiotic use – babies who are given antibiotics may be
50% more likely to develop asthma by the age of six
9. Pathogenesis
• Complex, not fully understood
• Large numbers of cells, mediators are involved and vascular leakage
-activated by expose to allergens or several mechanism
Inflammation
• Eosinophils, T-lymphocytes, macrophages and mast cell
Remodeling
• Deposition of collagens and matrix proteins-damage
• Loss of ciliated columnar cells- metaplasia – increase no of
secreting goblet cells
10. Inflammation of
inner lining of
airways
Muscle around
airways tighten
Airways produce
mucus due to
inflammation
Pathogenesis
12. Early phase
• Inhaled Antigen
Sensitised mast cells on the mucosal surface mediator
release.
Histamine bronchoconstriction, increased vascular
permeability.
prostaglandin D 2 bronchoconstriction, vasodilatation.
Leucotriene C4,D4, E4 Increased vascular permeability,
mucus secretion and bronchoconstriction.
Direct subepithelial parasympathetic stimulation
bronchoconstriction.
13. Late phase
• Starts 4 to 8 hours later
• Mast cell release additional cytokine
• Influx of leukocytes(neutrophil,eosinophil)
• Eosinophils are particularly important- exert a variety of effect
15. Differrence between normal airway and airway in person with asthma
Narrowed
bronchioles
(muscles spasms)
16.
17. Management of Chronic Asthma
Aims of management
• to recognize asthma
• to abolish symptoms
• to restore normal or best possible long term
airway function
• to reduce morbidity and prevent mortality
18. Approach of chronic asthma
• Education of patient and family
• Avoidance of precipitating factors
• Use of the lowest effective dose of convenient
medications minimizing short and long term
side effects.
• Assessment of severity and response to
treatment.
19. Medication
Bronchodilator drugs
•to relieve
bronchospasm and
improve symptoms.
Anti inflammatory
drugs
•to treat the airway
inflammation and
bronchial hyper-
responsiveness, the
underlying cause of
asthma, i.e. to prevent
attacks.
20.
21. Drug Delivery
• The inhaled route is preferred for beta2-agonists and steroids as it
produces the same benefit with fewer side effects
• Inhaled medications exert their effects at lower doses
• MDI is suitable for most patients as long as the inhalation technique
is correct
• Alternative methods include spacer devices, dry powder inhalers and
breath-actuated MDI
• Nebulized route is preferred in the management of acute attacks
22. The Need for New Asthma Therapy
• 5-10% have uncontrolled asthma despite effective inhaled therapy.
• What we need
– Drugs with similar mechanism but less side effects
– New classes of drug to treat asthma
– New classes of drug that modify the course of the disease
• Improvement in understanding basic pathophysiology of asthma in
molecular level
– IgE in pathogenesis of asthma
– Cytokines and cell signalling
– Immunomodulating pathway
24. New Bronchodilators
• Bronchodilators use
– Relieving bronchoconstriction (short-acting)
– Preventing bronchoconstriction (long-acting beta-agonist or
LABA: formoterol, salmeterol – lasting 12 hrs)
• Ultra-LABAs in development (lasting > 24 hrs) for once-daily use
• Long-acting muscarinic receptor agonist (LAMA), e.g. tiotropium,
can be a useful add-on for severe asthma.
• Bitter taste receptor (TAS2R) agonist can cause bronchodilation.
25. Bitter Taste Receptor (TAS2R) Agonist
Bitter taste receptor agonist can cause bronchodilator via
G-protein-phosphatidylinositol phosphate pathway
resulting in activation of Ca-dependent K channel and
subsequent hyperpolarization of smooth muscle cell.
26. Magnesium sulphate
• Reduces cytosolic calcium in airway smooth muscles leading to
bronchodilatation
• Can be given by IV/nebulisation
• Useful as an additional drug to SABA in acute severe asthma
• Not suitable to be employed alone as clinical benefit is small
• Cheap, well tolerated with minor s/e like nausea and flushing
27. Potassium channel openers
• Potassium channel openers that open calcium activate large conductance
K+ channels in smooth muscles.
• Experimental evidence and preclinical models suggest that ATP-dependent
K(+) (K(ATP)) channel openers, big-conductance K(+) (BK(CA)) channel
openers, and intermediate-conductance K(+) (IK(CA)) channel blockers
may be the most effective agents for treating asthma and COPD.
• Modulation of potassium channels by these agents may produce beneficial
effects such as bronchodilation, a reduction in airways hyper-
responsiveness (AHR), a reduction in cough and mucus production and an
inhibition in airway inflammation and remodelling.
Calcium channel blockers
• Nifedipine, verapamil
• Prevent calcium entry into smooth muscle
• Inhibit stimuli induced bronchoconstriction but no effect on basal airway
caliber
• Bronchodilator effect less than SABA.
28.
29. ANP
• Activates membrane guanylyl cyclase cGMP
bronchodilatation
• Bronchodilator effects comparable to SABA
• Useful for additional bronchodilatation in acute severe asthma
VIP analouges
• VIP binds to VPAC1 (smooth muscles of blood vessels) & VPAC2
(airway smooth muscles)couple to Gsadenylyl cyclase
stimulated smooth muscle relaxation
• VIP potent bronchodilator in vitro studies but in patients it is
rapidly metabolised and also has vasodilator S/E
• More stable analouge of VIP (RO25-1533) selectively stimulate
VPAC2 produces rapid bronchodilatation.
30. New Corticosteroids
• Designing new corticosteroids to decrease side
effects
• Dissociated steroids
• Nonsteroidal selective glucocorticoid receptor
agonists
31. • ICSs are the most effective anti-inflammatory therapy for asthma.
• Currently available ICSs can be absorbed from the lung, leading to
potential systemic side effects.
• New corticosteroids’ preferred properties
– Reduced absorption from the lungs
– Inactivated in the circulation
– Dissociated steroid (trans-activation vs cis-activation vs trans-
repression)
– Nonsteroidal selective glucocorticoid receptor agonist (SEGRA)
32. Transcription Mechanism of Corticosteroid
• Most of the anti-inflammatory effects of corticosteroid are due to
trans-repression of the pro-inflammatory gene.
• corticosteroid-GR complex is needed to attach to nuclear factor
leading to inhibition of gene expression.
• Dimerization of corticosteroid-GR complexes is needed for trans-
activation and cis-repression.
• Most of the side effects (osteoporosis, HTN, DM) of steroid are from
gene trans-activations.
33.
34. Dissociated Steroid/SEGRA
• Dissociated steroid and selective glucocorticoid receptor agonist can
bind to glucocorticoid receptor and prevent dimerization. This will
prevent trans-activation and cis-repression of metabolic gene
products.
• However, trans-activation of anti-inflammatory protein will be
prevented leading to decreased anti-inflammatory effects.
• Mapracorat, Fosdagrocorat, Dagrocorat
35.
36. Targeting Lipid Mediators
• Problems: More than 100 mediators are involved in the complex
inflammatory process in asthma.
• The only mediator antagonists available are cysteinyl-Leukotriene
CysLT1 receptor antagonists e.g. montelukast.
• 5’-lipooxygenase and 5’-lipooxygenase-activating protein inhibitors
are in development.
37. • Prostaglandin D2 is released from mast cells, Th2 cells and dendritic
cells.
– DP2 receptor (CRTh2) chemotaxis of Th2 and eosinophil
– DP1 receptor vasodilation, enhancing Th2 polarization
– Thromboxane receptor airway smooth muscle constriction
• CRTh2 inhibitors: AMG-853 OC000459 and MK-2746
• DP1/DP2 inhibitors: in development
• PGD2 synthesis inhibitors: in development
38. Interleukin-4 and Interleukin-13
• Pitrakinra
– Mutated IL-4 (recombinant human IL-4 mutein)
– Blocking IL-4Rα, the common receptor for IL-4 and IL-13
– Reduces the late response to inhaled allergen in mild asthmatics
– Patients with high eosinophil count have a decrease in asthma
exacerbation on pitrakinra.
39. Interleukin-5
• IL-5 is important for eosinophilic inflammation.
• Mepolizumab is a blocking antibody to IL-5.
– Depletes eosinophil from the circulation and the sputum of
asthmatics
– Reduces exacerbation in patients with persistent sputum
eosinophilia despite high dose ICS but no improvement in lung
function.
• IL-5Rα blocker is currently studied.
40. Other Interleukins
• Anti-TNF-α
– No beneficial effect on lung function, symptoms, or
exacerbations
– Increased reports of pneumonia and cancer
• IL-17
– May be a target in severe asthma with neutrophillic
inflammation
• IL-10
– Broad spectrum of antiinflammatory effects
– Efficacy has not been demonstrated in asthma.
• IL-12 and Interferons
– Not effective and results in unacceptable side effects
41. Phosphodiesterase-4 inhibitors
• PDE 4 inhibitors have wide spectrum of anti-inflammatory effects –
inhibiting T cells, eosinophils, mast cells, airway smooth muscle
• Roflumilast – inhibitory effect on allergen-induced response similar
to low dose ICSs.
• Side effects: nausea/vomiting mediated through PDE4D while
PDE4B decreases inflammation.
• PDE-3 inhibitor can cause bronchodilation.
• Roflumilast can inhibit both the early and late phase response in
patients with mild allergic asthma.
42.
43. Other novel anti-inflammatory drugs
• Adhesion molecule blockade
– Adhesion molecules play important role in recruitment of
inflammatory cells from the circulation to the airways.
• PPAR (peroxisome proliferator-activated receptor)-γ agonist
– Wide spectrum of anti-inflammatory effects
– Polymorphism of PPARγ gene is linked to increased risk of
asthma
– Rosiglitazone marginally improves lung function in smoking
asthmatics.
– Rosiglitazone 8 mg/day helps improve FEV1 and FEF in
smokers with asthma.
44. Anti-IgE therapy
• Omalizumab, monoclonal antibody that blocks IgE, is now used in
treatment of selected patients with severe asthma.
• More potent anti-IgE antibodies are in development.
• Low-affinity IgE receptor (FcεRII or CD23) antagonist seems to be
well tolerated and reduces IgE concentrations in patient with mild
asthma in a phase I study.
45. Mast cell Inhibitors
• Mast cell stabilizers
– Cromones (Sodium cromoglycate, nedocromil sodium)
– Furosemide
– Short-acting, not effective as long-term controllers
• Stem cell factor (SCF)
– Key regulator of mast cell survival
• Masitinib
– A potent tyrosine kinase inhibitor.
– Reduction in steroid use and symptoms in patients with severe
steroid-dependent asthma.
Syk kinase Inhibitors
• Spleen tyrosine kinase is involved in activation of mast cells and
other immune cells.
• Still in pre-clinical studies for asthma
46. Targeting Treg and Dendritic cells
• Specific immunotherapy increases Treg numbers and their
expression of IL-10 suppressed Th2 responses decrease IgE
synthesis
• Several classes of drug have been shown to suppress myeloid
dendritic cell activation
– iloprost
– fingolimod
• In preclinical development
47.
48. Bronchial thermoplasty
• Bronchial Thermoplasty, delivered by the Alair™ System, is a
treatment for severe asthma approved by the FDA in 2010
• It involves the delivery of controlled, therapeutic radiofrequency
energy to the airway wall,
• thus heating the tissue and reducing the amount of smooth muscle
present in the airway wall..
49.
50. Conclusion
• With the understanding of pathogenesis of asthma new targets can
be found in the drug development.
• Future drugs will be associated with less side effects and toxicity.
• As of now the drugs in current use are possibly the best that can be
offered to a asthma patient.